News – Page 428 – Endpoints News

SUBSCRIBE

AbbVie hustles its unicorn drug Rova-T into the clinic in combo with Bristol's Opdivo

5 years ago

Shire bags a quick thumbs up for its newly won cancer drug pipeline

5 years ago

Are 'great' tweeters born? Or can they be made? A conversation with Adam Feuerstein.

5 years ago

Top stories of the week: Thumbs up/Thumbs down

5 years ago

Pfizer/Spark team gets a ‘breakthrough’ in gene therapy alliance

5 years ago

Funded for PhII, biotech entrepreneurs achieve a 15-year-old R&D dream

5 years ago

Exhibit A in Valeant’s blockbuster R&D boast runs into trouble at the FDA

5 years ago

What’s the hottest biotech R&D field in venture investing?

5 years ago

Rhythm eyes a pivotal test after rolling through PhII with upbeat results for rare obesity cases

5 years ago

With biosimilars gaining momentum, Amgen and Allergan cite success of Herceptin's copycat

5 years ago

The Scangos legacy: A blockbuster MS record with lingering doubts about the pipeline

5 years ago

Sidelined at the FDA, AstraZeneca watches as new team seizes rival drug in $1.5B Relypsa buyout

5 years ago

New CEO Szela cuts Aegerion staff again, pulls Juxtapid out of the EU

5 years ago

BioRegnum: Another great reason emerges for AstraZeneca to target new biotech deals

5 years ago

Merck is scouting sites for a new research hub in the Bay Area, plans new hires

5 years ago

AstraZeneca culls its neuroscience team, exits Kendall Square office

5 years ago

By the numbers: 2-year tally of Celgene's biotech partnership deals tops $3B in cash

5 years ago

AveXis wins the inside track at the FDA with gene therapy ‘breakthrough’

5 years ago

Synthorx lines up some big synthetic biology R&D goals after grabbing a $10M round

5 years ago

Beleaguered Zafgen crushed after FDA demands force it to dump lead drug

5 years ago

Valeant wins first round in $445M gamble on brodalumab approval

5 years ago

Merck KGaA blueprints a $115M 'collaboration campus' for Massachusetts

5 years ago

Merck-backed Quartet places biotech vet Gerhard Koenig at the helm

5 years ago

Celgene signs Jounce as its new biotech star in $2.6B ‘immuno-oncology 2.0’ pact

5 years ago

First page Previous page 425 426 427428429 430 431 Next page Last page